Share this article →

Search articles

NICE announce public meeting for Ruxolitinib technology appraisal

 Posted on 14th December 2023  2 minute read

The National Institute for Health and Care Excellence (NICE) have this week released the registration facility for the committee meeting for the above appraisal, to be held on 11 January 2024. The meeting will be held virtually, using Zoom, a secure web conferencing tool.

Why is this meeting important?

NICE use the single technology appraisal process for new technologies – usually new pharmaceutical products or licence extensions for existing products. This process enables them to produce guidance soon after the technology is introduced in the UK and the process is key to make decisions about whether a product is approved for use through the NHS.

The link to register directly on Zoom is available on this page:

This meeting is a hugely important step for those in our community seeking to gain more treatment options for the management of vitiligo.

Your role as an observer

As a public observer, you will be able to listen to the business of the meeting, except where confidential information is being discussed, however, you will not be able to:

  • participate in committee discussions
  • ask questions, take part in voting or put your views to members of the committee

For further information about meetings in public please refer to the following document: Common questions and answers about virtual committee meetings.

The meeting agenda

The meeting will run from 8:45am to 3:00pm, although this may be subject to change. Joining links and times for each appraisal/topic and further instructions will be sent 1-2 days before the meeting.

Please note that this agenda is a draft and is subject to change before the meeting.

  1. Welcome and introduction to format of meeting – Part 1 only (open session)
  2. Apologies – Part 1 only (open session)
  3. Any other business – Part 1 only (open session)
  4. Minutes from the last committee meeting held on Thursday 14 December 2023 – Part 1 only (open session)
  5. Appraisal of fenfluramine hydrochloride for treating Lennox-Gastaut seizures in people aged 2 and over [ID1651]
    • 5.1. Introduction by the Chair, Dr Megan John – Part 1 only (open session)
    • 5.2. Declaration of interests – Part 1 only (open session)
    • 5.3. Presentation by lead team – Dr Will Sullivan, Dr Raju Reddy and TBC – Part 1 AND part 2 (open and closed session)
    • 5.4. Agreement on the content of the  Draft Guidance (DG) or Final Draft Guidance (FDG) – Part 2 only (closed session)
  6. Appraisal of ruxolitinib for treating non-segmental vitiligo in people 12 years and over [ID3998]
    • 61. Introduction by the Chair, Dr Megan John – Part 1 only (open session)
    • 6.2. Declaration of interests – Part 1 only (open session)
    • 6.3. Presentation by lead team – Dr Matt Bradley, Dr Ben Searle and Carole Pitkeathley – Part 1 AND part 2 (open and closed session)
    • 6.4. Agreement on the content of the  Draft Guidance (DG) or Final Draft Guidance (FDG) – Part 2 only (closed session)

Should you have any queries regarding observing this meeting, please contact NICE representative, Sana Issa.

Please support our work! You've enjoyed 1 article this month and we hope you have found it useful. Our work is entirely funded by memberships and donations, so please consider joining our charity today and supporting our work.

Become a Member